Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations

ConclusionReal-world evidence shows that the presence of ANA is behind an important percentage of patients treated with natalizumab that experience IRE, as well as DE but in a lower degree. These findings support the need to systematically evaluate ANA towards a personalized management of these patients to avoid undesired complications.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research